Abstract 2430
Background
Colorectal mucosa associated lymphoid tissue (MALT) lymphoma (CML) is rare and comprises only 2.5% of the MALT lymphomas. Its etiology and treatment are not well established. The aim of this systematic literature review is trying to characterize CML and analyzing treatment failure cases treated with various therapeutic strategies.
Methods
We reviewed cases reports on colorectal lymphoma from 1993 to 2017. A PubMed search of the English medical literature was conducted using the search words "colon," "rectum," and "Maltoma" or “MALT lymphoma” as filters. Through the review, 65 case reports were found, of which 15 case reports were excluded, due to literature written in languages other than English, poorly documented cases and combined colonic disease such as adenocarcinoma or inflammatory bowel disease. After all, 67 patients reported in 50 studies were included from PubMed search. And we added 6 patients treated for CML in our multicenter institutes. Risk factor analysis was done for treatment failure, defined as remission failure and recurrence.
Results
Of 73 patients diagnosed as CML, tumors were located in rectum in 54 patients (74.0%), 10 patients (13.6%) in right colon, 3 patients (4.1%) in the transverse colon and 6 patients (8.2%) in the sigmoid colon. The patients were achieved complete response (CR) with surgery (18/19cases), local resection (18/19 cases), chemotherapy (12/13 cases), radiation therapy (4/5cases), or antibiotics therapy including Helicobacter pylori (H. pylori) eradication (12/15 cases) in the first-line treatment. Eight cases (10.9%) needed second-line treatment for remission failure, CR was achieved in 5. The tumor recurrence occurred in 5 patients in remission patients (6.8%). The multivariable analysis showed that male, multiple tumor, first-line treatment failure was significantly related with treatment failure (p = 0.03, p = 0.05, p = 0.03, respectively).
Conclusions
Complete regression of primary CML was achieved using various therapeutic strategies. The first-line treatment failure, multiple tumors were associated with treatment failure, although the numbers of failure cases are too small to draw definitive conclusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3409 - Effect and safety of immune checkpoint inhibitors for brain metastases from non-small cell lung cancer
Presenter: Toshihiko Iuchi
Session: Poster Display session 1
Resources:
Abstract
3683 - Impact of Radiotherapy on efficacy of anti-programmed death 1 (PD-1) antibodies in metastatic NSCLC
Presenter: Evangeline Samuel
Session: Poster Display session 1
Resources:
Abstract
3924 - Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real World Data from a European Cohort with focus on subgroups of interest
Presenter: Giannis Mountzios
Session: Poster Display session 1
Resources:
Abstract
3970 - Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany. Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Martin Sebastian
Session: Poster Display session 1
Resources:
Abstract
5350 - The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)
Presenter: Motohiro Tamiya
Session: Poster Display session 1
Resources:
Abstract
3832 - Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): analysis of patients with central nervous system (CNS) metastases in a real-world study (ASTRIS)
Presenter: Giulio Metro
Session: Poster Display session 1
Resources:
Abstract
4082 - Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI)
Presenter: Riyaz Shah
Session: Poster Display session 1
Resources:
Abstract
2855 - Impact of ramucirumab (RAM) + erlotinib (ERL) on EGFR mutations in circulating tumor DNA – The 1st report of a biomarker study in Japanese patients from RELAY: Global Ph3 study of ERL + RAM or placebo (PL) in 1L metastatic NSCLC with EGFR activating mutations
Presenter: Kazuto Nishio
Session: Poster Display session 1
Resources:
Abstract
2911 - Apatinib combined with EGFR - TKI in treating advanced non-small cell lung cancer with EGFR - TKI resistance
Presenter: Ruifen Tian
Session: Poster Display session 1
Resources:
Abstract
2100 - Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
Presenter: Takashi Ninomiya
Session: Poster Display session 1
Resources:
Abstract